GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-28	NT$22.85	0.00%	149,170
26-07-27	NT$22.85	-0.87%	76,217
26-07-24	NT$23.05	-1.07%	108,553
26-07-23	NT$23.30	-0.64%	163,583
26-07-22	NT$23.45	-0.85%	98,706

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 2026-07-28			5-day change	1st Jan Change
22.85 ^TWD	0.00%		-3.38%	-11.26%

06-10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.57B 79.42M 69.7M 64.9M 59.69M 112M 7.59B 114M 770M 301M 3.76B 298M 292M 13B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.35B 72.63M 63.74M 59.36M 54.59M 102M 6.94B 104M 704M 276M 3.44B 273M 267M 11.89B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

06-10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
25-10-29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
25-08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-12	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
25-05-27	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI

1 week	-3.38%
Current month	-10.74%
1 month	-7.11%
3 months	-0.87%
6 months	-20.10%
Current year	-11.26%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	22.5	23.5
1 month	22.5	26.7
Current year	22.1	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	2018-12-31
Dih Fen Wu DFI	Director of Finance/CFO	-	2009-12-31
Yao Hua Lue IRC	Investor Relations Contact	-	2012-11-11

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	2001-01-31
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	2012-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	0.00%	-3.38%	-4.59%	-25.33%	79.51M
LONZA GROUP AG	+0.14%	-0.67%	-0.88%	+11.02%	47.74B
REVOLUTION MEDICINES, INC.	-2.24%	+0.31%	+393.45%	+615.13%	39.98B
BEONE MEDICINES AG	+1.40%	+3.69%	+12.21%	+46.79%	36.23B
IQVIA HOLDINGS INC.	+13.94%	+20.49%	+22.85%	+7.42%	35.59B
CELLTRION, INC.	-0.73%	+3.38%	+4.94%	+41.45%	27.91B
ASCENDIS PHARMA A/S	+0.40%	-0.30%	-	-	16.71B
MEDPACE HOLDINGS, INC.	-3.12%	+7.39%	+26.03%	+124.08%	16.45B
EUROFINS SCIENTIFIC SE	+2.39%	-1.64%	+4.74%	+9.95%	13.21B
ICON PUBLIC LIMITED COMPANY	+6.79%	+8.17%	-4.97%	-28.52%	12.93B
Average	+1.90%	+2.42%	+50.42%	+89.11%	24.68B
Weighted average by Cap.	+2.10%	+2.54%	+76.08%	+130.53%

	2024	2025
Net sales	14.7M 454K 399K 371K 341K 640K 43.38M 651K 4.4M 1.72M 21.51M 1.7M 1.67M 74.33M	37.86M 1.17M 1.03M 956K 879K 1.65M 112M 1.68M 11.34M 4.44M 55.41M 4.39M 4.3M 191M
Net income	-230M -7.1M -6.23M -5.8M -5.33M -10M -678M -10.17M -68.79M -26.93M -336M -26.64M -26.06M -1.16B	-235M -7.27M -6.38M -5.94M -5.46M -10.24M -694M -10.41M -70.44M -27.57M -344M -27.28M -26.69M -1.19B
Net Debt	-442M -13.66M -11.98M -11.16M -10.26M -19.24M -1.3B -19.57M -132M -51.82M -647M -51.27M -50.16M -2.24B	-220M -6.79M -5.96M -5.55M -5.1M -9.56M -648M -9.73M -65.79M -25.75M -322M -25.48M -24.93M -1.11B